Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment

Circulation

Volumn 96, Issue 4, 1997, Pages 1117-1121

  Kereiakes, Dean J ^a,d   Kleiman, Neal ^b   Ferguson, James J ^a   Runyon, John Paul ^a   Broderick, Thomas M ^c   Higby, Nancy A ^d   Martin, Linda H ^d   Hantsbarger, Gary ^e   McDonald, Shawn ^e   Anders, Robert J ^e  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Ohio Heart and Vascular Center   (United States)

^d The Carl & Edyth Lindner Center for Research & Education   (United States)

^e PFIZER INC   (United States)

Author keywords

Antagonists, receptor; Myocardial infarction; Stents; Thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; XEMILOFIBAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DOSE RESPONSE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; STENT; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

EID: 17744404249     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.4.1117     Document Type: Article

References (24)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
2. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FL, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, duMee CP, Califf RM, Topol EJ, for the IMPACT Investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation. 1995;91:2151-2157.
3. Neumann FJ, Gawaz M, Ott I, May A, Mossmer G, Schomig A. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol. 1996;27:15-21.
4. Zidar JP, Kruse KR, Thel MC, Kereiakes DJ, Muhlestein JB, Davidson CJ, Teirstein PS, Tenaglia A, Yakubov SJ, Popma JJ, Tanguay JF, Kitt MM, Lorenz TJ, Tcheng JE, Lincoff AM, Califf RM, Topol EJ. Integrelin for emergency coronary artery stenting. J Am Coll Cardiol. 1996;27:138A. Abstract.
5. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stenting. N Engl J Med. 1996;334:1084-1089.
6. Makkar RR, Eigler NL, Nakamura M, Litvack FI, Badimon L, Jordan R, Bramfitt J, Kaul S. Monoclonal antibody to IIb/IIIa receptor (m7E3) is highly effective in inhibiting acute stent thrombosis. Circulation. 1995;92(suppl I):I-685. Abstract.
7. Aggarwal RJ, Ireland DC, Azrin MA, Ezekowitz MD, deBono DP, Gershlick AH. Antithrombotic properties of stents eluting platelet glycoprotein IIb/IIIa antibody. Circulation. 1995;92(suppl I):I-488. Abstract.
8. Simpfendorfer C, Kottke-Marchant K, Topol EJ. First experience with chronic platelet GP IIb/IIIa receptor blockade: a pilot study of xemilofiban an orally active antagonist in unstable angina patients eligible for PTCA. J Am Coll Cardiol. 1996;27:242A.
9. Kottke-Marchant K, Simpfendorfer C, Lowrie M, Burns D, Anders RJ. Sustained but variable inhibition of platelet aggregation with xemilofiban, an oral GP IIb/IIIa receptor antagonist, in patients with unstable angina. Circulation. 1995;92(suppl I):I-488. Abstract.
10. Leon MB, Baim, DS, Gordon P, Giambartolomei A, Williams DO, Diver DJ, Senerchia C, Fitzpatrick M, Popma JJ, Kurtz RE. Clinical and angiographic results from the Stent Anticoagulation Regimen Study (STARS). Circulation. 1996;94(suppl I):I-685. Abstract.
11. Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab administration for complex coronary intervention. Circulation. 1996;94:906-910.
12. Levine PH. The effect of thrombocytopenia on the determination of platelet aggregation. Am J Clin Pathol. 1976;65:79-82.
13. Trip MD, Gats VM, van Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990;322:1549-1554.
14. Anders RJ, Alexander JC, Hantsbarger GL, Burns DM, Oliver SD, Cole G, Fitzgerald DJ. Demonstration of potent inhibition of platelet aggregation with an orally active GP IIb/IIIa receptor antagonist. J Am Coll Cardiol. 1995;Feb(special issue):117A.
15. Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G, Ferraro M, Colombo A. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 1996;93:215-222.
16. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, Gaglione A, Goldberg SL, Tobis JM. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676-1688.
17. Lu Y, Theroux P, Xigo Z, Chitescu M. Increased expression of GP IIb/IIIa platelet membrane receptor in acute coronary syndromes. Circulation. 1996;94(suppl I):I-515. Abstract.
18. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Collier BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GP IIb/IIIa receptors. J Am Coll Cardiol. 1995;26:1665-1671.
19. Wencel-Drake J, Plow E, Zimmerman T, Painter R, Ginsberg M. Immuno-fluorescent localization of adhesive glycoprotein in resting and thrombin-stimulated platelet. Am J Pathol. 1984;115:156-164.
20. Michelson AD. Flow cytometry: a clinical test of platelet function. Blood. 1996;87:4925-4936.
21. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81-106.
22. The CAPRIE Steering Committee. A randomized trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet. 1996;348:1329-1339.
23. Savi P, Heilmann E, Nurden P, Laplace MC, Bihour C, Kieffer G, Nurden AT, Herbert JM. Clopidogrel: an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin Appl Thromb Hemost. 1996;2:35-42.
24. 3H]-2-methylthio ADP to rat platelets: effects of clopidogrel and ticlopidine. J Pharmacol Exp Ther. 1994;269:772-777.